Comparative evaluation of biosimilar Trastuzumab with reference Trastuzumab activity in HER2-positive breast cancer patients

AbdulHameed Saeed, Vana; AK. Mohammed, Nidhal

doi:10.22092/ari.2022.360239.2566

تعداد نشریات	281
تعداد نشریات سازمان	80
تعداد شماره‌ها	2,428
تعداد مقالات	28,188
تعداد مشاهده مقاله	16,162,333
تعداد دریافت فایل اصل مقاله	12,564,093

	Comparative evaluation of biosimilar Trastuzumab with reference Trastuzumab activity in HER2-positive breast cancer patients
Archives of Razi Institute
مقالات آماده انتشار، پذیرفته شده، انتشار آنلاین از تاریخ 02 آذر 1401
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2022.360239.2566
نویسندگان
Vana AbdulHameed Saeed ¹؛ Nidhal AK. Mohammed²
¹Hawler Medical University, College of Medicine. Department of Basic Science, Erbil, Iraq. Tel: 009647507692757 /
²Pharmacology Unit, Dept. Basic sciences, College of Medicine, Hawler Medical University/ email: nidhal.abdulkader@hmu.edu.krd
چکیده
Background One of the breast cancer subtypes, epidermal growth factor receptor 2 (HER2), accounts for 15% of all breast cancers and is characterized by aggressive behavior and a poor prognosis. For patients with HER2-positive breast cancer, trastuzumab, a monoclonal antibody that targets HER2 receptors, is prescribed in addition to chemotherapy to increase their chances of survival. However, the high expense of this therapy makes it impossible for patients in developing nations to easily afford to undergo this biological therapy. Trastuzumab biosimilars were consequently launched as a substitute that offers comparable effectiveness but at a reduced price. By monitoring serum levels of the tumor biomarker CA15-3 and evaluating NT pro-BNP for the adverse cardiac effects of both therapy in HER2 positive breast cancer patients before and after 6 cycles of biological therapy, this study compares the biological activity and cardiac safety of reference trastuzumab with biosimilar trastuzumab. Patients and Methods 36 females with metastatic and early stage HER2-positive breast cancer who visited the oncology department at Rizgary Hospital were included in this prospective research. The patients' ages ranged from 30 to 80. 18 individuals got reference trastuzumab, while the remaining 18 also received chemotherapy and biosimilar trastuzumab. Each patient had a data sheet created for them that contained details from hospital-reserved files.` Results In the Herceptin group, there is an insignificant difference in the median of CA15-3, No significant difference was detected between the means of NT proBNP before and after treatment. In the Biosimilar group, there was a significant reduction in the median CA15-3. Also for BNP, there is a significant increase in the level of NT proBNP before and after treatment Conclusion Evaluating the association of trastuzumab-induced cardiotoxicity during breast cancer treatment with different factors, we discovered that there may be an increased risk of cardiotoxicity after trastuzumab treatment
کلیدواژه‌ها
breast cancer؛ chemotherapy؛ HER2-positive breast cancer؛ reference trastuzumab؛ biosimilar trastuzumab

آمار تعداد مشاهده مقاله: 21

Journal Management System. Designed by sinaweb.

پیوندهای مفید

آمار

Comparative evaluation of biosimilar Trastuzumab with reference Trastuzumab activity in HER2-positive breast cancer patients